You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

SYMMETREL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Symmetrel, and what generic alternatives are available?

Symmetrel is a drug marketed by Endo Pharms and is included in three NDAs.

The generic ingredient in SYMMETREL is amantadine hydrochloride. There are seven drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the amantadine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Symmetrel

A generic version of SYMMETREL was approved as amantadine hydrochloride by UPSHER SMITH LABS on August 5th, 1986.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SYMMETREL?
  • What are the global sales for SYMMETREL?
  • What is Average Wholesale Price for SYMMETREL?
Summary for SYMMETREL
Drug patent expirations by year for SYMMETREL
Recent Clinical Trials for SYMMETREL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Columbia UniversityPhase 4
American Heart AssociationPhase 2
University of PittsburghPhase 2

See all SYMMETREL clinical trials

US Patents and Regulatory Information for SYMMETREL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms SYMMETREL amantadine hydrochloride CAPSULE;ORAL 016020-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Endo Pharms SYMMETREL amantadine hydrochloride SYRUP;ORAL 016023-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Endo Pharms SYMMETREL amantadine hydrochloride TABLET;ORAL 018101-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.